B1MGPlus: Beyond 1 Million Genomes Plus

Status: Active Start:
01/02/2025
End:
31/01/2028

Primary tabs

Description

The EU Member States initiative 1+ Million Genomes (1+MG) aims to enable secure access to genomic and corresponding clinicaldata across Europe, supporting research, health policy and personalised healthcare. This initiative follows a two-staged roadmap, viathe Beyond 1M Genomes and European Genomic Data Infrastructure projects, alongside 1+MG Working Groups and National MirrorGroups.

The Genome of Europe project will build a European network of national genomic reference cohorts. B1MGplus aims to support the scale up and sustainability of 1+MG by supporting Member States to create a federated Europeangenomics data infrastructure based on a European Digital Infrastructure Consortium (EDIC). It will also facilitate the uptake ofgenomics into healthcare delivery and public health policy, while developing the guidelines for meta-data standards and data qualityassurance within the 1+MG Framework. B1MGplus activities include:

- Preparation of Genome EDIC: drafting of legal and policy documents for operational readiness, supporting GDI Pillar I for long-term sustainability, setting up risk management frameworks and stakeholder interaction plans.

- Facilitating strategic orientation of the 1+MG initiative.

- Facilitating the uptake of genomics for healthcare: promoting awareness and engagement of public health professionals, encouraging the maturity assessment of genomics in healthcare systems, creating a citizens' hub for disseminating information on genomics, supporting the demonstration of the economic impact of genomics medicine on healthcare.

- Developing data standards, ontologies, and sequencing practices to ensure that data made available is 1+MG-ready B1MGplus advances the 1+MG initiative, fostering genomic medicine and personalised healthcare.

This project will contribute to unlocking the promise of genomics for healthcare and public health, creating unprecedented opportunities in cancer, common and rare diseases, infectious diseases and pharmacogenomics.

Funding